Keywords: sb, jointly, commercialize, coulter, cancer, therapy, smithkline
SB To Jointly Commercialize Coulter's Cancer Therapy
Article | 08 December 1998
SmithKline Beecham and Coulter Pharmaceutical have agreed to jointlycommercialize Bexxar (I-131 Anti-B1 Antibody; iodine I-131 tositumomab), Coulter's leading candidate in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
